Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Zheng-Bo SONG"'
1
Akademický článek
A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
Autor: You-cai Zhu, Wen-xian Wang, Chun-wei Xu, Wu Zhuang, Zheng-bo Song, Kai-qi Du, Gang Chen, Tang-feng Lv, Yong Song
Publikováno v: Cancer Biology & Therapy, Vol 19, Iss 12, Pp 1097-1101 (2018)
In non-small cell lung cancer (NSCLC), driver gene alterations, such as EGFR, ALK, MET, and ROS1, are usually mutually exclusive. Few clinical cases with co-existing ROS1 fusion and de-novo MET amplification have been reported. In addition, the effic
Externí odkaz: https://doaj.org/article/9b7ae0f932f24e0aa83d261b00db2d57
Zobrazit plný text záznamu
2
Akademický článek
Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
Autor: Chun-wei Xu, Wen-xian Wang, Yan-ping Chen, Yu Chen, Wei Liu, Li-hua Zhong, Fang-fang Chen, Wu Zhuang, Zheng-bo Song, Xiao-hui Chen, Yun-jian Huang, Yan-fang Guan, Xin Yi, Tang-feng Lv, Wei-feng Zhu, Jian-ping Lu, Xiao-jiang Wang, Yi Shi, Xian-dong Lin, Gang Chen, Yong Song
Publikováno v: Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-10 (2018)
Abstract Background ALK rearrangement-advanced NSCLC patients respond to crizotinib. ALK rearrangement is currently determined with RT-PCR. VENTANA IHC is a standard method to identify ALK protein overexpression in NSCLC; however, VENTANA IHC has rar
Externí odkaz: https://doaj.org/article/670ffea6efa64531975757d75f66d41a
Zobrazit plný text záznamu
3
Akademický článek
Preoperative elevation of serum C-reactive protein as an indicator of poor prognosis for early-stage esophageal squamous cell carcinoma
Autor: Zheng-Bo Song, Bao-Chai Lin, Bo Li, Chun-Xiao He, Bei-Bei Zhang, Lan Shao, Yi-Ping Zhang
Publikováno v: Kaohsiung Journal of Medical Sciences, Vol 29, Iss 12, Pp 662-666 (2013)
Preoperative elevation of serum C-reactive protein (CRP) is reportedly associated with poor prognosis in several types of cancer. This study investigated the role of serum CRP as a prognostic factor in early-stage esophageal squamous cell carcinoma (
Externí odkaz: https://doaj.org/article/8418a207923c4752b31389fa1403cf7c
Zobrazit plný text záznamu
5
Definitive local therapy for extracranial single-organ oligorecurrent non-small-cell lung cancer: A single institutional retrospective study
Autor: Jia-Nan Jin, Peng Yue, Yue Hao, Shi-Yan Wu, Bai-Qiang Dong, Qing Wu, Zheng-Bo Song, Ming Chen
Publikováno v: Medicine. 101(46)
Oligometastatic non-small-cell lung cancer (NSCLC) is potentially curable. Oligo-recurrence occurs with oligometastatic disease characterized by well-controlled primary lesion. The purpose of the present study was to explore the value of definitive l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ea5324b1b03fb4c56785ed6926cee9d
https://pubmed.ncbi.nlm.nih.gov/36401441
Zobrazit plný text záznamu
6
The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study
Autor: Jing-Wen Wei, Yue Hao, Jing Xiang, Xing-Xiang Pu, Li-Ping Wang, Zhan-Sheng Jiang, Jing-Xun Wu, Qian Wang, Chun-Wei Xu, Wen-Xian Wang, Zheng-Bo Song
Publikováno v: Neoplasma. 69(6)
Pulmonary sarcomatoid carcinoma (PSC) is an aggressive and poorly differentiated type of non-small cell lung carcinoma. Because of the rarity of PSC, the efficacy and toxicity of immunotherapy remain unclear. Hence, the aim of this study was to evalu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef71528e9d0ad0719b86dfe39e37a37a
https://pubmed.ncbi.nlm.nih.gov/36353935
Zobrazit plný text záznamu
7
Predicting the efficacy of immune checkpoint inhibitors monotherapy in advanced non-small cell lung cancer: a machine learning method based on multidimensional data
Autor: Na Liu, Bi-Lin Liang, Lu Lu, Bing-Qian Zhang, Jing-Jing Sun, Jian-Tao Yang, Jie Xu, Zheng-Bo Song, Lei Shi
Background Immunotherapy has improved the prognosis of patients with advanced non-small cell lung cancer (NSCLC), but only a small subset of patients achieved clinical benefit. The purpose of our study was to integrate multidimensional data using a m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e466f1bcf76ef59ec82ee401d876c4
https://doi.org/10.21203/rs.3.rs-1688580/v1
Zobrazit plný text záznamu
8
Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer
Autor: Jin-Fei Si, Jing Xiang, Jing-Wen Wei, Yue Hao, Zheng-Bo Song
Publikováno v: Neoplasma. 69(4)
We aimed to explore the treatment efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung squamous cell carcinoma (SCC) patients and identify potential beneficial subgroups of EGFR-mutated lung SCC
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec0cb071f03bd511d855814394b6e5a
https://pubmed.ncbi.nlm.nih.gov/35603955
Zobrazit plný text záznamu
10
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
Autor: Xinghao Ai, Ziming Li, Zhiwei Chen, Hong Jian, Zhen Zhou, Zheng-bo Song, Shun Lu, Yongfeng Yu
Publikováno v: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Background Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), anti-HER2 antibody drug conjug
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541e6c7beda54a6449217a9a15607392
http://europepmc.org/articles/PMC8444597
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje